US 12,275,785 B2
Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of CXCL9 and other biomarkers
Cristina De Min, Basel (CH); Walter Ferlin, Basel (CH); and Fabrizio De Benedetti, Basel (CH)
Assigned to Swedish Orphan Biovitrum AG, Basel (CH)
Filed by Swedish Orphan Biovitrum AG, Basel (CH)
Filed on Dec. 14, 2020, as Appl. No. 17/121,513.
Application 17/121,513 is a division of application No. 15/149,633, filed on May 9, 2016, granted, now 11,034,760.
Claims priority of provisional application 62/246,949, filed on Oct. 27, 2015.
Claims priority of provisional application 62/221,393, filed on Sep. 21, 2015.
Claims priority of provisional application 62/158,153, filed on May 7, 2015.
Prior Publication US 2021/0101972 A1, Apr. 8, 2021
Int. Cl. A61P 7/00 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/24 (2006.01); G01N 33/68 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/249 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); G01N 33/6863 (2013.01); A61K 39/395 (2013.01); A61K 2039/505 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); G01N 2333/521 (2013.01); G01N 2800/24 (2013.01); G01N 2800/7095 (2013.01)] 10 Claims
 
1. A method of alleviating a symptom of macrophage activation syndrome, the method comprising detecting a level of CXCL9, alone or in conjunction with one or more other biomarkers in a biological sample from a subject, comparing the detected level of CXCL9 to a control level of expression, and when the detected level is elevated, administering an anti-interferon gamma (IFNγ) antibody or immunologically active fragment thereof to the subject, wherein the anti-IFNγ antibody or immunologically active fragment thereof comprises a variable heavy chain (VH) complementarity determining region (CDR) 1 comprising the amino acid sequence of SYAMS (SEQ ID NO: 1); a VH CDR2 comprising the amino acid sequence of AISGSGGSTYYADSVKG (SEQ ID NO: 2); a VH CDR3 comprising the amino acid sequence of DGSSGWYVPHWFDP (SEQ ID NO: 3); a variable light (VL) CDR1 comprising the amino acid sequence of TRSSGSIASNYVQ (SEQ ID NO: 4); a VL CDR2 comprising the amino acid sequence of EDNORPS (SEQ ID NO: 5); and a VL CDR3 comprising the amino acid sequence of QSYDGSNRWM (SEQ ID NO: 6).